Sanofi announced on Friday 19 October, having obtained a positive opinion of a committee of the european medicines Agency (EMA), in order to put on the market in Europe, its vaccine against dengue, which includes the overseas departments and overseas collectivities French, exposed to more. The committee for medicinal products for human use (CHMP) of the EMA recommended that the indication of the vaccine Dengvaxia for the elderly ” from 9 to 45 years of age who have already been infected by the virus and living in areas endemic “, according to a press release from Sanofi.

This could include the Caribbean, French Polynesia, or the island of The Meeting, has been hard hit this year by an outbreak of dengue fever, an infection transmitted by a mosquito. “The authorisation of the placing on the market of the european Commission is expected in December 2018,” said Sanofi.

also Read :   Why France refuses the vaccine against the dengue to its overseas territories

A scandal in the Philippines

Since the end of 2015, Dengvaxia has already obtained authorisation for placing on the market in twenty countries, including Mexico, Brazil, or the Philippines. But this the world’s first vaccine against dengue has so far been a commercial failure, resounding for the group, coupled with a scandal in the Philippines, where the authorities have accused of having caused the death of dozens of children.

Sanofi had warned the end of 2017 that Dengvaxia could aggravate the symptoms of the dengue fever in people who have never been infected previously by the virus. This announcement had created panic in the Philippines, where hundreds of thousands of children had already been vaccinated. Sanofi has, however, always firmly defended its vaccine and said it had never identified any deaths related to its administration. As to the authorities in the philippines, they have appeared by then divided on the matter.

last April, the world health Organization (WHO) has recommended testing patients individually before they inject Dengvaxia, in order to ensure that they have not been exposed earlier to this virus. Dengvaxia has been evaluated in clinical studies that included more than 40 000 people in fifteen countries, supplemented by studies of efficacy and tolerance, “large-scale” providing up to six years of follow-up to this day, according to Sanofi.

also Read :   Vaccination against dengue fever : the fiasco of Sanofi